Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
MorphoSys AG is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are distributed among 6 distinct examiners, meaning every pending matter is under the review of a different individual. These actions are spread across 5 distinct art units, indicating a diverse administrative landscape for the company's pharmaceutical portfolio. This fragmentation suggests that the company's biotechnology filings cover a variety of technical sub-specialties.
CHEN, PO-CHIH is the busiest examiner for the company, with 1 busiest examiner pending action. The fact that 6 distinct examiners are spread across 5 distinct art units requires a prosecution strategy that can adapt to the varying standards of multiple units and examiners. Practitioners must be prepared for a wide range of feedback, as the lack of significant overlap in art units and examiners minimizes the opportunity for consistent administrative outcomes. Managing the 6 pending office actions across 5 distinct art units requires a coordinated effort to ensure that the company's overall patent strategy remains coherent despite the diverse review process across multiple administrative divisions. The applicant should monitor the feedback from each unit to identify any emerging trends in pharmaceutical prior art interpretation.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §102 only | 1 (14%) |
| Double-patenting only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037120 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | NOLAN, JASON MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | WEBB, WALTER E | 37d overdue |
| 18289467 | MODULATORS OF TREX1 | RAO, PADMAJA S | 18d overdue |
| 18987624 | SYNTHESIS OF BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | — |
| 18290181 | USE OF PELABRESIB FOR TREATING ANEMIAS | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1629 | 1 |
| 1627 | 1 |
| 1623 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18987624 | SYNTHESIS OF BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | 1621 | §102 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18938453 | MODULATORS OF TREX1 | JACKSON, SHAWQUIA | — | DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18834256 | ANHYDROUS CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | SAMSELL, RILLA MARIE | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18290181 | USE OF PELABRESIB FOR TREATING ANEMIAS | SEITZ, ANTHONY JOSEPH | 1629 | §103 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18289467 | MODULATORS OF TREX1 | RAO, PADMAJA S | 1627 | DP | Final Rejection | 18d overdue | Pending | Nov 03, 2023 |
| 18037120 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | NOLAN, JASON MICHAEL | 1623 | §103§112Other | Non-Final OA | — | Pending | May 16, 2023 |
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | WEBB, WALTER E | 1612 | §103DP | Non-Final OA | 37d overdue | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial